RegenMed Teams with HyperFlex Medical to Revolutionize Bunion Treatment in a Rapidly Growing Market
September 2, 2025
RegenMed Teams with HyperFlex Medical to Revolutionize Bunion Treatment in a Rapidly Growing Market
Expanding Access to Bone-Preserving Bunion Care
RegenMed is excited to announce our new client, HyperFlex Medical, creator of the HyperFlex® Bunion Correction System — a minimally invasive, bone-preserving implant designed to treat approximately 93% of bunion patients with mild-to-moderate hallux valgus. This approach allows same-day weight-bearing and faster recovery for patients.
Note: HyperFlex brochure data.
Unpacking the Market Growth and Patient Demand
- Global bunion treatment market was valued at around USD 1.47 billion in 2023, projected to reach USD 2.33 billion by 2032, with aCAGR of 6.8%.
- Bunion correction systems (including implants and related devices) generated roughly USD 730.4 million in 2022, forecast to reach USD 1.2 billion by 2030, at a 6.9% CAGR.
- Bunion surgery market alone stood at USD 437.8 million in 2023, expected to hit USD 606.1 million by 2029, growing at 5.7% CAGR.
- Regionally,US, EU4, UK, and Japan bunion market totaled USD 567.2 million in 2024, projected to rise to USD 1.02 billion by 2035, at 5.49% CAGR.
(All projections based on industry market reports.)
Size of the Patient Population & Clinical Workforce
Patients Suffering from Bunions
- About 23% of adults (18–65 years) have some degree of hallux valgus; the figure rises to 36% in individuals over 65 years.
(EPRA Journals) - Globally,the average prevalence of hallux valgus is around 19%, with variations by region andage.
(BioMed Central, Wikipedia) - In Western countries, it's estimated that as many as one-third of the population will develop bunions — especially common among women.
(podiatryfaq.com)
Physicians Treating Bunions
- The American College of Foot and Ankle Surgeons (ACFAS) includes over 7,700 foot and ankle surgeons (podiatrists) in the U.S.
(Wikipedia) - The American Orthopaedic Footand Ankle Society (AOFAS) comprises around 2,400 orthopedic foot and ankle surgeons.
(Wikipedia)
Together, these two professional bodies represent more than 10,000 U.S. clinicians specializing in bunion and foot and ankle disorders.
Why HyperFlex® Matters in This Landscape
With up to 36% of older adults affected by bunions — and up to 19%globally — there’s a pressing need for effective, patient-friendly treatments. HyperFlex® answers this need:
- Minimally invasive: Small incision, no bone cutting, motion preservation.
- Fast recovery: Same-day walking, reduced healing times.
- Strong and reliable: Implant is 12× stronger than clinical load requirements.
RegenMed’s Role and Vision
By partnering with HyperFlex Medical, RegenMed is aligning with its mission to deliver real-world, effective early interventions that improve outcomes and reduce the burden of more complex surgeries.
Benefits include:
- Empowering clinicians to treat earlier, less invasively.
- Helping payers manage costs tied to surgical interventions.
- Providing patients with faster, more effective relief.
Contact us to learn more.
RegenMed Teams with HyperFlex Medical to Revolutionize Bunion Treatment in a Rapidly Growing Market
September 2, 2025
Expanding Access to Bone-Preserving Bunion Care
RegenMed is excited to announce our new client, HyperFlex Medical, creator of the HyperFlex® Bunion Correction System — a minimally invasive, bone-preserving implant designed to treat approximately 93% of bunion patients with mild-to-moderate hallux valgus. This approach allows same-day weight-bearing and faster recovery for patients.
Note: HyperFlex brochure data.
Unpacking the Market Growth and Patient Demand
- Global bunion treatment market was valued at around USD 1.47 billion in 2023, projected to reach USD 2.33 billion by 2032, with aCAGR of 6.8%.
- Bunion correction systems (including implants and related devices) generated roughly USD 730.4 million in 2022, forecast to reach USD 1.2 billion by 2030, at a 6.9% CAGR.
- Bunion surgery market alone stood at USD 437.8 million in 2023, expected to hit USD 606.1 million by 2029, growing at 5.7% CAGR.
- Regionally,US, EU4, UK, and Japan bunion market totaled USD 567.2 million in 2024, projected to rise to USD 1.02 billion by 2035, at 5.49% CAGR.
(All projections based on industry market reports.)
Size of the Patient Population & Clinical Workforce
Patients Suffering from Bunions
- About 23% of adults (18–65 years) have some degree of hallux valgus; the figure rises to 36% in individuals over 65 years.
(EPRA Journals) - Globally,the average prevalence of hallux valgus is around 19%, with variations by region andage.
(BioMed Central, Wikipedia) - In Western countries, it's estimated that as many as one-third of the population will develop bunions — especially common among women.
(podiatryfaq.com)
Physicians Treating Bunions
- The American College of Foot and Ankle Surgeons (ACFAS) includes over 7,700 foot and ankle surgeons (podiatrists) in the U.S.
(Wikipedia) - The American Orthopaedic Footand Ankle Society (AOFAS) comprises around 2,400 orthopedic foot and ankle surgeons.
(Wikipedia)
Together, these two professional bodies represent more than 10,000 U.S. clinicians specializing in bunion and foot and ankle disorders.
Why HyperFlex® Matters in This Landscape
With up to 36% of older adults affected by bunions — and up to 19%globally — there’s a pressing need for effective, patient-friendly treatments. HyperFlex® answers this need:
- Minimally invasive: Small incision, no bone cutting, motion preservation.
- Fast recovery: Same-day walking, reduced healing times.
- Strong and reliable: Implant is 12× stronger than clinical load requirements.
RegenMed’s Role and Vision
By partnering with HyperFlex Medical, RegenMed is aligning with its mission to deliver real-world, effective early interventions that improve outcomes and reduce the burden of more complex surgeries.
Benefits include:
- Empowering clinicians to treat earlier, less invasively.
- Helping payers manage costs tied to surgical interventions.
- Providing patients with faster, more effective relief.
Contact us to learn more.
